相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications
Ilias D. Vachliotis et al.
DIABETES OBESITY & METABOLISM (2022)
RANKL Impairs the TLR4 Pathway by Increasing TRAF6 and RANK Interaction in Macrophages
Ryerson Fonseca Mota et al.
BIOMED RESEARCH INTERNATIONAL (2022)
Osteoprotegerin Expression in Liver is Induced by IL13 through TGF beta
Adhyatmika Adhyatmika et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2022)
Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing
Stergios A. Polyzos et al.
MEDICAL HYPOTHESES (2021)
Diabetes mellitus: 100 years since the discovery of insulin
Stergios A. Polyzos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis
Blanca T. Pacheco-Soto et al.
JOURNAL OF DRUG ASSESSMENT (2021)
Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity
Rossella Del Toro et al.
ENDOCRINE (2021)
Plasma osteoprotegerin as a biomarker of poor glycaemic control that predicts progression of albuminuria in type 2 diabetes mellitus: A 3-year longitudinal cohort study
Angela Mei Chung Moh et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
Stergios A. Polyzos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
RANKL induces beige adipocyte differentiation in preadipocytes
Flavia Sayuri Matsuo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2020)
RANKL Is Involved in Runx2-Triggered Hepatic Infiltration of Macrophages in Mice with NAFLD Induced by a High-Fat Diet
Li Zhong et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Osteoprotegerin Is more than a Possible Serum Marker in Liver Fibrosis: A Study into Its Function in Human and Murine Liver
Adhyatmika Adhyatmika et al.
PHARMACEUTICS (2020)
Circulating Receptor Activator of Nuclear Factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study
Olivier Bourron et al.
CARDIOVASCULAR DIABETOLOGY (2020)
OPG Production Matters Where It Happened
Masayuki Tsukasaki et al.
CELL REPORTS (2020)
Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease
Doaa El Amrousy et al.
CYTOKINE (2020)
Plasma Levels and Gene Expression of RANK in Non-Alcoholic Fatty Liver Disease
Abolghasem Hadinia et al.
CLINICAL LABORATORY (2020)
Osteoprotegerin increases parallel to insulin resistance in obese adolescents
Eleni P. Kotanidou et al.
ENDOCRINE RESEARCH (2019)
Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPAR-γ-CD36 Pathway
Cheng Zhang et al.
DIABETES (2019)
Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus
I Barchetta et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)
Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters Effect of denosumab on glycemic parameters
Ichiro Abe et al.
MEDICINE (2019)
Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes
A. Mantovani et al.
DIABETES & METABOLISM (2019)
Off-label uses of denosumab in metabolic bone diseases
Stergios A. Polyzos et al.
BONE (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Polyzos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
Athanasios D. Anastasilakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Pharmacotherapy of type 2 diabetes: An update
Jagriti Upadhyay et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease
Lucia Pacifico et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease
Hannah Forde et al.
CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM (2018)
Relationship between insulin resistance, hs-CRP, and body fat and serum osteoprotegerin/RANKL in prediabetic patients
Oktay Bilgir et al.
MINERVA ENDOCRINOLOGICA (2018)
Mechanisms of diabetes mellitus-induced bone fragility
Nicola Napoli et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis
Katrine Hygum et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Circulating osteoprotegerin in postmenopausal osteoporotic women: marker of impaired glucose regulation or impaired bone metabolism
Margarita Mashavi et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2017)
A dipose tissue, obesity and non-alcoholic fatty liver disease
Stergios A. Polyzos et al.
MINERVA ENDOCRINOLOGICA (2017)
Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy
Ahmed M. Abu El-Asrar et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)
Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults
M. Monseu et al.
DIABETES & METABOLISM (2016)
Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: A case-control study in China
Yixin Niu et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL
Emma Harper et al.
VASCULAR PHARMACOLOGY (2016)
Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report
Ayumu Takeno et al.
BMC ENDOCRINE DISORDERS (2016)
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
Stella Bernardi et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children
Meltem Erol et al.
IRANIAN RED CRESCENT MEDICAL JOURNAL (2016)
Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes
Alireza Esteghamati et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2015)
Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes
Yixin Niu et al.
BMC CARDIOVASCULAR DISORDERS (2015)
Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway
Nagesha Guthalu Kondegowda et al.
CELL METABOLISM (2015)
A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women
Elena Passeri et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study
Yixin Niu et al.
BMC ENDOCRINE DISORDERS (2015)
Osteoprotegerin in relation to insulin resistance and blood lipids in sub-Saharan African women with and without abdominal obesity
Clarisse Noel Ayina Ayina et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy
Gehua Yu et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2015)
Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis
Mei Yang et al.
PLOS ONE (2015)
Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification
Carmen Perez de Ciriza et al.
CLINICAL BIOCHEMISTRY (2014)
Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus
S. Tavintharan et al.
DIABETES & VASCULAR DISEASE RESEARCH (2014)
RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy
Agbor Ndip et al.
DIABETOLOGIA (2014)
Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice
Vagelis Rinotas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Below-Knee Arterial Calcification in Type 2 Diabetes: Association With Receptor Activator of Nuclear Factor κB Ligand, Osteoprotegerin, and Neuropathy
Olivier Bourron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes
Stella Bernardi et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
The Relation Between Carotid Intima Media Thickness and Serum Osteoprotegerin Levels in Nonalcoholic Fatty Liver Disease
Teslime Ayaz et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2014)
Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
Atsushi Aoki et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
Hyun-Seuk Moon et al.
ENDOCRINE REVIEWS (2013)
The association of insulin resistance with serum osteoprotegerin in obese adolescents
Joanna Suliburska et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2013)
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus
Stefan Kiechl et al.
NATURE MEDICINE (2013)
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver
Giovanni Musso et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications
Mette Bjerre
SPRINGERPLUS (2013)
Rosiglitazone Decreases Plasma Levels of Osteoprotegerin in a Randomized Clinical Trial with Type 2 Diabetes Patients
Mads Nybo et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2011)
Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass
P. Dimitri et al.
BONE (2011)
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
Henrik Reinhard et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus
Mikael K. Poulsen et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice
Ganesh V. Halade et al.
EXPERIMENTAL GERONTOLOGY (2011)
Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets
Barbara Toffoli et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2011)
Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects
David T. Ashley et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy
Yu-Hung Chang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes
Alev E. Altinova et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2011)
Protective Role of Black Tea Extract against Nonalcoholic Steatohepatitis-Induced Skeletal Dysfunction
Subhra Karmakar et al.
JOURNAL OF OSTEOPOROSIS (2011)
Osteoprotegerin and Mortality in Type 2 Diabetic Patients
Henrik Reinhard et al.
DIABETES CARE (2010)
Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes
Eoin P. O'Sullivan et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients
M. Nybo et al.
DIABETIC MEDICINE (2010)
Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women
Iraj Nabipour et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease
Yusuf Yilmaz et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2010)
A polymorphism near osteoprotegerin gene confer risk of obesity in Uyghurs
Xiao-yan Jiang et al.
ENDOCRINE (2010)
Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients
Masami Ishiyama et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes
G. D. Xiang et al.
DIABETIC MEDICINE (2009)
One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Meta-analysis of gene expression in human pancreatic islets after in vitro expansion
B. Kutlu et al.
PHYSIOLOGICAL GENOMICS (2009)
Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes
Baris Akinci et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals:: results from both cross-sectional and interventional study
Marie-Helene Gannage-Yared et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: A randomized, controlled trial
A. D. Anastasilakis et al.
HORMONE AND METABOLIC RESEARCH (2008)
Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women
Betul Ugur-Altun et al.
ARCHIVES OF MEDICAL RESEARCH (2007)
Expression and regulation of osteoprotegefin in adipose tissue
Juan-Ji An et al.
YONSEI MEDICAL JOURNAL (2007)
Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death
J. Schrader et al.
DIABETOLOGIA (2007)
An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction
Paola Secchiero et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Is a gene important for bone resorption a candidate for obesity?: An association and linkage study on the RANK (receptor activator of nuclear factor-κB) gene in a large Caucasian sample
Lan-Juan Zhao et al.
HUMAN GENETICS (2006)
The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects
DV Anand et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients
A Avignon et al.
DIABETES CARE (2005)
The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity
B Ugur-Altun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
分享论文
